UNSPSC 51433903: Nifedipine

This classification denotes a calcium channel blocker with the molecular formula C17H18N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I9ZF7L6G2L, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-, dimethyl ester (8ci) but generally known as nifedipine, which bears US NIH Compound Identifier 4485. European Medicines Agency schedules Nifedipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09253MIG.

UNSPSC 51433903 Nifedipine, a Commodity code, covers pharmaceutical products state and local governments procure for emergency medical services, pharmacy benefit programs, and institutional health care delivery. Recent solicitations show state and local buyers purchasing nifedipine and related advanced life support medications, often as part of broader multi-drug purchases for fire rescue services and pharmacy benefit programs. The work involves supplying finished pharmaceutical products with specific strength, dosage form, and packaging; meeting FDA cGMP and Drug Supply Chain Security Act compliance; maintaining shelf-life and expiration-date requirements; and managing logistics including delivery timelines, product replacement for expired stock, and distribution through authorized wholesalers or direct procurement channels. Issuing bodies include city procurement departments purchasing for municipal emergency medical services (fire rescue), state health and human services agencies developing pharmacy benefit programs, and cooperative purchasing alliances spanning multiple state and local jurisdictions.

The City of Tampa issued IFB 26P00188 in April 2026 soliciting advanced life support medications including nifedipine and related agents for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, marking an exploratory phase for potential future formal procurement. Recent activity spans Florida, Texas, and the Minnesota–Oregon cooperative purchasing region, with municipal emergency response and state pharmacy benefit programs as primary use cases.